Biotechnology company Replimune Group, Inc. (REPL) announced Tuesday the appointment of Emily Hill as Chief Financial Officer. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics.Emily brings in more than 15 years of experience in the biotechnology and life sciences industry, having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies.Prior to joining Replimune, Emily held numerous positions at PTC Therapeutics where she headed up Investor Relations before becoming the Company's Chief Financial Officer..

生物技术公司Replimune Group，Inc。（REPL）星期二宣布任命Emily Hill为首席财务官。希尔最近是商业阶段生物技术公司PTC Therapeutics的CFO。艾米莉在生物技术和生命科学行业拥有超过15年的经验，在几家领先的公共生物技术和制药公司担任高级财务管理和投资者关系角色。在加入Replimune之前，Emily在PTC Therapeutics担任过许多职位，在那里她在成为该公司的首席财务官之前领导了投资者关系。。

Prior to PTC Therapeutics, Emily was Director of Investor Relations at Warner Chilcott where she was responsible for leading the function until the Company was acquired by Actavis for approximately $8.5 billion.Additionally, Hill was Senior Manager of Investor Relations at Genzyme Corporation. Prior to Genzyme, Emily was a Biotech Equity Research Associate at Summer Street Partners.

在PTC Therapeutics之前，Emily是Warner Chilcott投资者关系总监，负责领导该职能，直到该公司被Actavis收购约85亿美元。此外，希尔还是Genzyme Corporation投资者关系的高级经理。在Genzyme之前，Emily是Summer Street Partners的生物技术股权研究助理。

For comments and feedback contact: editorial@rttnews.comBusiness News.

有关意见和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票